Neuromodulation, Made Measurable

We’re pioneering a neuromodulation platform that provides real-time visibility into the brain’s response to stimulation.

Built on decades of research.
Engineered to see and respond.

Incubated at Mayo Clinic and engineered by Cadence, our Biomarker Targeted Stimulation (BTS) system uses patient-specific brain biomarkers to guide and adapt stimulation.

See How It Works

of the population has epilepsy

people with epilepsy in the U.S.

in costs worldwide

Beginning with epilepsy

For people living with focal drug-resistant epilepsy, seizures can stand in the way of an independent life. Cadence is developing a platform for personalized neuromodulation, with the first goal of helping more people achieve seizure freedom.

Learn More

Studying personalized neuromodulation in epilepsy

The BTSEE clinical trial marks the beginning of an important phase of learning and collaboration with leading comprehensive epilepsy centers. We reach this foundational milestone after years of technical and scientific preparation.

learn more about our clinical trial

We’re a team of experts who get it

The Cadence team brings decades of expertise in neuroscience, engineering, and clinical innovation. And, we’re backed by partners and advisors who never lose sight of who we’re working for.

Meet Our Team

Real progress for patients and families

I would not trade it with anything. There was no life before the implant for me.

We are beyond thrilled with the results of J’s surgery and can now see her living a more independent life.

Had no seizures for 16 months in a row. Had one seizure on Halloween night 2017, and seizure free since then.

It was life changing, we recommended to people already.

Working a full time job. Back to school enrolled in undergraduate program, finished college.

Patient experiences are from a case series conducted using a prototype version of Cadence’s therapy.

Tune in to our podcast

Hosted by our CTO and CSO, this podcast shares the journey toward ending epileptic seizures. Kent and Doug’s conversations with expert guests, such as top doctors in neuroscience, investigate the impact epilepsy has and the work being done locally and globally to ensure every person lives a seizure-free life.

Novel therapy, proven technology

Cadence Neuroscience is proud to closely collaborate with Mayo Clinic in raising the standard for epilepsy care. Mayo Clinic’s research and clinical leadership have shaped the evolution of neuromodulation technology where it has been used with success over the past several decades. Cadence’s therapy is using this tested hardware with new software.

Latest Insights

Explore All Insights
  • Cadence Neuroscience logo

    October 14, 2026

    Cadence Neuroscience Receives FDA IDE Approval to Begin Multicenter Study of its Biomarker Targeted Stimulation Therapy for Focal Drug-Resistant Epilepsy

  • Headshot of Chris Cronin

    September 22, 2026

    Cadence Neuroscience Appoints Medtech Executive Chris Cronin as CEO to Lead Clinical Execution and Platform Growth

  • Cadence Neuroscience logo

    July 10, 2026

    Newsletter July 2026 | Cadence Reaches an Important Milestone